Menerba: Phase III ongoing

An independent DSMB recommended continuation of the double-blind, placebo-controlled U.S. Phase III MF101-004 trial based on safety data from 66 patients who received Menerba for >=30 days. Last month, Bionovo halted enrollment in the trial at 280 patients due to lack of funding. The company said it will need to raise funds to either complete a smaller Phase IIb trial with the 280 enrolled patients or complete the Phase III trial as planned. The Phase III trial, which began in 4Q11, planned to evaluate 5 and 10 g/day Menerba for 12 weeks in about 1,200 postmenopausal women. ...